Ocuphire Pharma Investor Updates

3 Agenda and Participants Phase 2 Trial Topline Readout As Planned In 2Q21 ● ● ● Topline VEGA-1 Phase 2 Clinical Trial Results for Nyxol and Low-Dose Pilocarpine in Presbyopia Presbyopia Market Opportunity Future Milestones Q&A Participants Mina Sooch, MBA, President and CEO Mitch Brigell, PhD, Head of Clinical Development Jay Pepose, MD, Medical Advisory Board & Corporate Board Member Susan Benton, Corporate Board Member Charlie Hoffmann, MBA, VP of Corporate Development and Operations Amy Rabourn, MAcc, VP of Finance Ocuphire PHARMA

View entire presentation